Biotin and Micardis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Biotin (biotin) and Micardis (telmisartan). Common drug interactions include fatigue among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Biotin and Micardis. It is created by eHealthMe based on reports of 63 people who take the same drugs from the FDA, and is updated regularly.

What is Biotin?

Biotin has active ingredients of biotin. It is often used in hair loss. eHealthMe is studying from 35,393 Biotin users. Check the latest studies of Biotin.

What is Micardis?

Micardis has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 27,605 Micardis users. Check the latest studies of Micardis.



On Jul, 08, 2026

63 people who take Biotin and Micardis together, and have interactions are studied.

Biotin and Micardis drug interactions.

What are the common drug interactions of Biotin and Micardis, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Chronic kidney disease
  3. Renal failure (kidney dysfunction)
  4. Headache (pain in head)
  5. Sinusitis (inflammation of sinus)
  6. Cough
  7. Fungal infection
  8. Immunoglobulins increased
  9. Infusion site erythema (reddening of the skin at infusion site)
  10. Infusion site pruritus (severe itching at infusion site)

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Upper respiratory tract infection
  3. Cardiovascular disorder (heart diseases)
  4. Oedema (fluid collection in tissue)
  5. Skin oedema (swelling of skin)
  6. Sinus disorder (disease of sinus)
  7. Skin fissures (a crack in the skin)
  8. Drug ineffective
  9. Irritable bowel syndrome
  10. Tunnel vision (the loss of peripheral vision with retention of central vision)

What are the common drug interactions of Biotin and Micardis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Bone marrow failure
  2. Immunodeficiency
  3. Renal impairment (severely reduced kidney function)
  4. Staphylococcal infection (an infection with staphylococcus bacteria)
  5. Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)

10-19:

n/a

20-29:

  1. Oligohydramnios (a condition in pregnancy characterized by a deficiency of amniotic fluid)
  2. Premature delivery

30-39:

n/a

40-49:

  1. Abdominal discomfort
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Cardiovascular disorder (heart diseases)
  4. Multiple allergies (allergy to multiple agents)

50-59:

  1. Skin discolouration (change of skin colour)
  2. Skin ulcer
  3. Sleep disorder
  4. Surgery
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Adverse drug reaction
  7. Back pain
  8. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  9. Burning sensation
  10. Craniotomy

60+:

  1. Fatigue (feeling of tiredness)
  2. Arthralgia (joint pain)
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Sinusitis (inflammation of sinus)
  5. Chronic kidney disease
  6. Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
  7. Dyspnoea (difficult or laboured respiration)
  8. Fungal infection
  9. Infusion site haemorrhage (bleeding from infusion site)
  10. Irritability

What are the existing conditions these people have? *

  1. Arthritis (form of joint disorder that involves inflammation of one or more joints): 8 people, 12.70%
  2. Diabetes: 7 people, 11.11%
  3. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 6 people, 9.52%
  4. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 6 people, 9.52%
  5. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 7.94%
  6. Primary Immunodeficiency Syndrome: 5 people, 7.94%
  7. Immunodeficiency Common Variable: 5 people, 7.94%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 7.94%
  9. High Blood Cholesterol: 5 people, 7.94%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 7.94%

* Approximation only. Some reports may have incomplete information.

Do you take Biotin and Micardis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Biotin and Micardis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Biotin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Micardis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Biotin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Micardis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on biotin and telmisartan (the active ingredients of Biotin and Micardis, respectively), and Biotin and Micardis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: